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A B S T R A C T
129 Wada procedures were reviewed to examine the suitability of propofol (n = 54) as a replacement to
amobarbital (n = 75) for use as an anaesthetic in the Wada test. Suitability was considered with respect
to length of hemiplegia induced, the frequency of side effects and patient memory scores. Data was
retrospectively collected from records of patients who had undergone the Wada procedure between
2004 and 2009 in Beaumont Hospital, Dublin. No signiﬁcant differences were found between the two
drugs on any of the measures. The results suggest that propofol represents a suitable alternative to
amobarbital for use in the Wada procedure.
 2012 Published by Elsevier Ltd on behalf of British Epilepsy Association.
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The Wada test is a procedure generally used to establish
hemispheric dominance of language and identify contralateral
memory reserve prior to respective surgery for temporal lobe
epilepsy. Between 2003 and 2004 there was an international
shortage in the availability of amobarbital. As a result, alternative
anaesthetics and methods for the Wada test were sought.1 Since
2006, the alternative anaesthetic adopted for use in Beaumont
Hospital is propofol. Propofol has been used as an anaesthetic for
Wada testing in some centres prior to the shortage of amobarbi-
tal.2–4 Mikuni et al.5 evaluated the adverse effects associated with
intracarotid propofol testing in a mixed neurosurgical sample
(n = 58) and found that 33% of their patients (19 patients) exhibited
side effects to propofol. They sub-classiﬁed side effects based on
severity into grades one, two and three (illustrated in Table 1).
Mikuni et al.5 reported six patients exhibiting Grade 1 side effects,
six patients with Grade 2 side effects and seven with Grade 3 side
effects.
Mikati et al.6 compared amobarbital (n = 25) and propofol
(n = 15) as anaesthetics in a sample of neurosurgical patients
undergoing a Wada test with respect to time to the return of motor
power and time to return of verbal and non-verbal responses. They
concluded that there was no signiﬁcant difference between* Corresponding author at: Department of Psychology, Lower Ground Floor,
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restoration or verbal and non-verbal responses. More recently, a
full review of alternative anaesthetics used in Wada testing7 found
that propofol resulted in an increase in tone and rhythmic
twitching that hindered the completion of the procedure. This
emphasises the need for further investigation to assess propofol’s
use as an anaesthetic agent in the Wada procedure. The present
study endeavoured to compare the usefulness of propofol as an
alternate anaesthetic to amobarbital for use in the Wada test.
2. Methods
The data for the present study was acquired retrospectively
from records of patients who underwent a Wada procedure
between January 2004 and July 2009. The Beaumont Hospital
Ethics (Medical Research) Committee granted ethical approval for
the study. Patients were identiﬁed by reviewing records from the
Department of Psychology in Beaumont Hospital, Dublin, between
2004 and 2009. Propofol and amobarbital Wada procedures were
compared with respect to the length of hemiplegia induced
number of side effects observed and memory performance and
pass/fail rates of the test.ee A pass on the test is calculated using the binomial theorem for 4-item alternate
forced choice design. It provides the measure of recall in the procedure. 16 items
were chosen in a 4-item alternate forced choice design giving a pass rate of 8/16
(p < .0001).
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Table 1
Side effects as classiﬁed by Mikuni et al.5
Grade 1
Eye pain
Shivering
Face contortion
Lacrimation
Laughing
Apathy
Grade 2
Confusion
Involuntary head movement
Involuntary eye movement
Involuntary body movement
Grade 3
Increased muscle tone
Twitching
Rhythmic movements
Tonic posture
Table 2
Frequency of side effects for propofol and amobarbital.
Propofol Amobarbital
No. of cases % of cases No. of cases % of cases
Grade one 12 21.8% 15 19.5%
Grade two 4 7.3% 5 6.5%
Grade three 0 0.0% 0 0.0%
No side effects 39 70.9% 57 74.0%
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The cerebral angiography procedure associated with achieving
a Wada test is outlined elsewhere.8 The Wada test is conducted in a
radiography suite, which is fully equipped to deal with any
complications that may arise during the procedure. Once
hemiplegia is induced, language functions are assessed by
presenting the patient with a range of stimuli, which they are
asked to name. Patients are then asked to attend to several
receptive speech tasks and read a number of sentences. If the
patient’s dominant hemisphere is anaesthetised, the patient will
be unable to respond. Once these tasks are completed, patients are
presented with 16 separate visual and verbal stimuli, which they
are asked to remember. The duration of anaesthetic affect is
measured by assessing hemiplegia at planned, regular intervals
throughout the procedure. After the protocol has been completed,
there is a time delay of 10 min before the recall phase of the
memory component of the test. This consists of a four-choice
alternate recognition task in which patients are shown 16 sets of
either four pictures or four words, each set including a picture or
word previously presented during the test. Patients are encouraged
to make their best guess. In Beaumont Hospital it is standard
practice to only conduct a unilateral Wada test. This is conducted
ispilateral to the proposed site of resection, this is now standard
practice in several international epilepsy centres.9 There is ongoing
debate internationally regarding whether the side of injection
should ipsilateral or contralateral to the intended area of resection.
3. Results
3.1. Demographic characteristics
In total, 129 Wada procedures were reviewed. The sample
consisted of 57 males and 72 females. The age range in the propofol
group was 21–60 years with a mean age of 38.37 years. The age
range in the amobarbital group was 17–61 years with a mean age
of 37.90 years. The characteristics of the sample with respect to the
Wada test are as follows, 54 patients underwent a Wada test using
propofol, of these 28 patients underwent an inject right, test left
Wada procedure, 26 patients underwent an inject left, test right
Wada procedure. The remaining 75 underwent the procedure
using amobarbital, of this group 40 patients underwent an inject
right, test left Wada procedure, 35 patients underwent an inject
left, test right Wada procedure. All of the patients reviewed for this
study were pre-surgical candidates for selective anterior temporal
lobectomy due to drug resistant epilepsy.
Chi square and t-test analyses indicated that there was no
signiﬁcant difference between the propofol and amobarbitalpatient groups with respect to gender (Chi square = 1.123, df = 1,
p = .263), handedness (Chi square = 1.307, df = 1, p = .193) or age at
time tested (t = .269, df = 149, p = .515).
An independent samples t-test examining the difference in
length of time to end of hemiplegia between amobarbital and
propofol was conducted. No signiﬁcant difference (t = 1.686,
p = .065, df = 88) between propofol (M = 299.03 [s], SD = 135.208
[s]) and amobarbital (M = 249.27 [s], SD = 117.124 [s]) was found
with respect to time to end of hemiplegia. An independent samples
t-test was conducted to compare memory scores, out of a total of
16, between amobarbital (M = 10.82, SD = 4.678) and propofol
(M = 11.93, SD = 4.568). This was also found not to be signiﬁcant
(t = 1.346, p = .181, df = 128). A further two independent samples t-
tests were also conducted to determine if there was a signiﬁcant
difference in memory scores with regard to amobarbital and
propofol based on side of injection. There was not found to be any
signiﬁcant difference (t = .119, df = 50.3, p = .905) for left sided
injections between amobarbital (M = 9.77, SD = 4.6) and propofol
(M = 9.92, SD = 5.1). However, there was found to be a signiﬁcant
difference (t = 2.81, df = 56.5, p = .007) between memory scores for
right sided injections between amobarbital (M = 11.77, SD = 4.72)
and propofol (M = 14.19, SD = 2.13). The correlation between the
length of time to end of hemiplegia and memory score was
calculated for each drug and no signiﬁcant relationships were
found for either propofol (r = .142, N = 54, p = .306) or amobarbital
(r = .046, N = 75, p = .695).
With respect to the number of patients passing or failing the
procedure, Chi-Square analysis indicated that there was no
signiﬁcant difference (Value = 1.643, df = 1, p = .201) between
propofol (Pass = 81.5%, Fail = 18.5%) and amobarbital (Pass = 69.3%,
Fail = 30.7%). Examination of Yates’ Continuity Correction revealed
no signiﬁcant difference between the two anaesthetics with
respect to Pass/Fail rates (Value = 1.159, df = 1, p = .282). A second
Chi square test was performed to examine the difference between
the two anaesthetics amobarbital and propofol with respect to the
number of side effects experienced by each patient group, as
categorised by Mikuni et al.3 There was no signiﬁcant difference in
the number and type of side effects-experienced between either of
the anaesthetics (Value = .157, df = 2, Asymp. Sig. = .924). A
breakdown of the frequency and type side-effects experienced
by the propofol and amobarbital groups is illustrated in Table 2.
4. Discussion
The aim of the present study was to examine the suitability of
propofol, as a replacement to amobarbital, for use in the Wada test.
To date, this is the largest study to directly address this issue and
also the ﬁrst study to utilise an epilepsy only sample. There was no
signiﬁcant difference between propofol and amobarbital with
respect to Pass/Fail rates, side effects or length of hemiplegia, thus
indicating that propofol represents a suitable alternative to
amobarbital for use in the Wada test. The number of side-effects
observed in the present study are reduced compared to those
observed by Mikuni et al.5 particularly in relation to Grade 3 side-
effects. Mikuni et al.5 reported Grade 3 side effects in seven
patients, accounting for an incident rate of 12% of their sample,
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observed in either the propofol or amobarbital group. There are
two possible explanations for this. Firstly, Mikuni et al.4 found the
occurrence of Grade 3 side-effects to be correlated to a dosage of
propofol of 15 Mg or more. In the present study, only 5 patients
received a dose of propofol greater than 13 Mg. Mikuni et al.4 also
found there to be a correlation between the incidence of Grade 3
side-effects and patients older than 55 years. Again, in the present
study, there were only 3 patients with an age greater than 55 years.
Secondly, Mikuni et al’s patient sample was mixed, consisting of
patients with brain tumours, epilepsy and arteriovenous mal-
formations, whereas the present study utilised a temporal lobe
epilepsy only sample. Although not signiﬁcant, it was observed
that the period of hemiplegia induced by propofol was longer than
the period of hemiplegia induced by amobarbital. Although this
ﬁnding has no impact on the overall, the lengthier period of
hemiplegia offered by propofol is beneﬁcial during such a time
constrained procedure. These ﬁndings provide good evidence that
propofol represents a suitable alternative to amobarbital for use in
the Wada procedure.
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